Role of capecitabine in treating metastatic colorectal cancer in Chinese patients

Abstract

The China Food and Drug Administration approved the use of capecitabine in patients with metastatic colorectal cancer (mCRC) in 2004. This paper reviews the available information of capecitabine in Chinese patients with mCRC, focusing on its effectiveness and safety against mCRC. Identification of all eligible studies was made by searching the PubMed and Wanfang database from 2000 to 2013. Published data examining various aspects of clinical response and tolerability with capecitabine alone or in combination with other chemotherapeutic or biological agents for first- and second-line mCRC were examined. Capecitabine and its combination displayed high efficacy in Chinese patients with mCRC. Toxicities are generally manageable, and elderly patients can tolerate capecitabine well.

Expression profile of innate immune receptors, NLRs and AIM2, in human colorectal cancer: correlation with cancer stages and inflammasome components

“…It is ranked the third most common cancer among males and females in the United States according to Cancer Statistics for 2015. Recent data have shown that the incidence rates of CRC has rapidly increased in China [ 5 ]. As a majority of patients are still diagnosed at a late stage, biomarkers that may allow early diagnosis are crucial [ 5 ].…”

“…Recent data have shown that the incidence rates of CRC has rapidly increased in China [ 5 ]. As a majority of patients are still diagnosed at a late stage, biomarkers that may allow early diagnosis are crucial [ 5 ]. Inflammatory molecules represent a possible source of CRC biomarkers, because the molecular pathobiology of CRC implicates pro-inflammatory conditions as promoting factors in the malignant progression of the tumor, invasion, and metastasis.…”

Vaccines for colorectal cancer: an update

“…Also, it has been demonstrated that stereotactic radiotherapy can be effective in dealing with lung metastatic patients . To improve the survival chance, systemic chemotherapy can be used as an adjuvant to surgery in the form of 5‐FU or perioperative FOLFOX administration for 6 months in patients with resectable liver metastases, as a neo‐adjuvant to achieve resectability of initially unresectable disease in the form of FOLFOX and FOLFIRI (5‐FU, leucovorin, and irinotecan) with similar response rates (approximately 30%) or FOLFOXIRI (oxaliplatin, irinotecan, and 5‐FU) with higher response rates (66%) and as a palliative therapy including 5‐FU or capecitabine with 12‐month survival; FOLFOX, FOLFIRI, or XELOX (oxaliplatin plus capecitabine) with 15‐month survival …”

“…38 To improve the survival chance, systemic chemotherapy can be used as an adjuvant to surgery in the form of 5-FU or perioperative FOLFOX administration for 6 months in patients with resectable liver metastases, 39 as a neoadjuvant to achieve resectability of initially unresectable disease in the form of FOLFOX and FOLFIRI (5-FU, leucovorin, and irinotecan) with similar response rates (approximately 30%) 40 or FOLFOXIRI (oxaliplatin, irinotecan, and 5-FU) with higher response rates (66%) 41 and as a palliative therapy including 5-FU or capecitabine with 12-month survival; FOLFOX, FOLFIRI, or XELOX (oxaliplatin plus capecitabine) with 15-month survival. 42 Immunotherapy faces with cancer through strategies which elevate the antitumor immune responses by focusing on the immunosuppressive pathways, such as mAB and cancer vaccines. 43 Immunotherapy has yielded several mAB drugs which accompanying with the chemotherapy can establish the first and second line of treatment and improve the survival rate in metastatic CRC patients.…”

Serum Unsaturated Free Fatty Acids: A Potential Biomarker Panel for Early-Stage Detection of Colorectal Cancer

“…Colorectal cancer (CRC) is the third most common cancer and the fifth most frequent cause of cancer deaths in China 1 . Clinical data show that 5-year survival rate of early-stage CRC postoperative patients is around 90% 2 .…”